Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models
Document Type
Journal Article
Publication Date
9-24-2020
Journal
Journal of Medicinal Chemistry
Volume
63
Issue
18
DOI
10.1021/acs.jmedchem.0c00567
Abstract
© 2020 American Chemical Society. Selective inhibition of histone deacetylase 6 (HDAC6) is being recognized as a therapeutic approach for cancers. In this study, we designed a new HDAC6 inhibitor, named Suprastat, using in silico simulations. X-ray crystallography and molecular dynamics simulations provide strong evidence to support the notion that the aminomethyl and hydroxyl groups in the capping group of Suprastat establish significant hydrogen bond interactions, either direct or water-mediated, with residues D460, N530, and S531, which play a vital role in regulating the deacetylase function of the enzyme and which are absent in other isoforms. In vitro characterization of Suprastat demonstrates subnanomolar HDAC6 inhibitory potency and a hundred- to a thousand-fold HDAC6 selectivity over the other HDAC isoforms. In vivo studies reveal that a combination of Suprastat and anti-PD1 immunotherapy enhances antitumor immune response, mediated by a decrease of protumoral M2 macrophages and increased infiltration of antitumor CD8+ effector and memory T-cells.
APA Citation
Noonepalle, S., Shen, S., Ptáček, J., Tavares, M., Zhang, G., Stránský, J., Pavlíček, J., Ferreira, G., Hadley, M., Pelaez, G., Bařinka, C., Kozikowski, A., & Villagra, A. (2020). Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models. Journal of Medicinal Chemistry, 63 (18). http://dx.doi.org/10.1021/acs.jmedchem.0c00567